The IVO-LUNG Study

Sponsor
Sun Yat-sen University
Study ID
NCT07204548
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Non Small Cell Lung Cancer (Stage III)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Ivonescimab — DRUG
    Ivonescimab is given after definitive concurrent/sequential chemoradiotherapy

Study Details

This Phase II, open-label, single-arm study evaluates the efficacy and safety of one-year Ivonescimab consolidation therapy in patients with unresectable Stage III NSCLC who have not progressed after definitive chemoradiotherapy.

Key Dates

Start date
Oct 31, 2025
Status verified
Sep 2025
Primary completion
Oct 31, 2027
Completion
Oct 31, 2029

Study Design

Enrollment
63 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ivonescimab as consolidation after definitive concurrent/sequential chemoradiotherapy
    Ivonescimab as consolidation after definitive concurrent/sequential chemoradiotherapy. Ivonescimab is given by 20mg/kg BW,q3w, last for one year.

Primary Outcome Measure

12-month PFS rate [ Time Frame: From the date of enrollment untill 12 month ]

Central Contacts